Skip to main content
TipRanks
Go Ultimate75% OFF

Syngene International Ltd. (SYNGENE) AI Stock Analysis

7 Followers
IN:SYNGENE

Syngene International Ltd.

(NSE:SYNGENE)

Select Model
Rating:66Neutral
Price Target:INR 480.00â–²(10.59% Upside)
Action:reiterated
Date:10/29/26

Solid financial performance with a strong balance sheet and reliable cash generation is the primary positive driver, offset by expensive valuation and mixed technical signals showing short-term strength but longer-term resistance.

Positive Factors
Integrated CRDMO platformSyngene’s integrated CRDMO model spans discovery, development, analytical work, and commercial-scale manufacturing across small molecules and biologics. This breadth can deepen client relationships, support repeat business, and improve the company’s ability to capture value across multiple stages of drug development.
Negative Factors
FY2026 revenue contractionThe sharp FY2026 revenue decline interrupts Syngene’s prior multi-year expansion and indicates a meaningful near-term setback in demand, project activity, or delivery. If sustained, lower revenue would reduce operating leverage and make it harder to maintain the historical scale benefits of the platform.

Syngene International Ltd. (SYNGENE) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%IN:SYNGENE-30.85%INDA-5.15%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 148.36B
Dividend Yield
0.29%
Average Volume (3M)
173.53K
Price to Earnings (P/E)
93.8
Beta (1Y)
0.91
Revenue Growth
-5.99%
EPS Growth
-60.30%
Country
India
Employees
6,692
Sector
General
Sector Strength
55
Industry
Specialty Business Services

Syngene International Ltd. Business Overview & Revenue Model

Company Description

Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The c...

Syngene International Ltd. Financial Statement Overview

Summary

Strong balance sheet with low leverage and growing equity, supported by consistent operating cash flow and revenue expansion, though 2026 projections indicate margin compression and negative revenue growth.

Income Statement

72Positive

Balance Sheet

85Very Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue35.22B37.39B36.42B34.89B31.93B26.04B
Gross Profit11.39B12.62B24.41B23.50B21.56B17.12B
EBITDA8.23B9.13B10.47B10.73B9.84B7.43B
Net Income1.86B3.17B4.96B5.10B4.64B3.96B
Balance Sheet
Total Assets66.58B70.55B67.96B61.52B58.31B55.64B
Cash, Cash Equivalents and Short-Term Investments5.30B12.89B13.97B10.77B13.54B12.81B
Total Debt5.07B4.58B5.78B5.55B8.15B10.22B
Total Liabilities18.00B22.16B20.69B18.94B22.13B22.66B
Stockholders Equity48.59B48.39B47.27B42.58B36.18B32.98B
Cash Flow
Free Cash Flow06.11B3.98B5.50B3.05B1.05B
Operating Cash Flow09.55B11.68B10.42B8.38B5.81B
Investing Cash Flow0-9.11B-7.45B-4.96B-6.88B-6.12B
Financing Cash Flow0-2.04B-1.42B-5.51B-3.40B-313.00M

Syngene International Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price434.05

Price Trends

50DMA389.19Positive
100DMA400.68Positive
200DMA419.26Positive

Market Momentum

MACD16.49Negative
RSI61.85Neutral
STOCH72.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SYNGENE, the sentiment is Positive. The current price of 434.05 is above the 20-day moving average (MA) of 408.35, above the 50-day MA of 389.19, and above the 200-day MA of 419.26, indicating a bullish trend. The MACD of 16.49 indicates Negative momentum. The RSI at 61.85 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SYNGENE.

Syngene International Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:SYNGENE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ANTHEMIN:ANTHEM77OutperformINR 520.80B84.72―0.22%-1.20%18.53%
IN:SYNGENEIN:SYNGENE66NeutralINR 175.21B93.81―0.29%-5.99%-60.30%
IN:CONCORDBIOIN:CONCORDBIO65NeutralINR 116.17B41.14―1.36%4.02%-12.81%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:BIOCONIN:BIOCON47NeutralINR 585.55B120.20―0.14%5.70%-24.72%
IN:PANACEABIOIN:PANACEABIO47NeutralINR 21.68B-304.05――19.43%―
IN:DCALIN:DCAL43NeutralINR 20.40B29.96――-20.86%-34.51%

* General Sector Average

Performance Comparison

-25%0%25%50%IN:SYNGENEIN:BIOCONIN:CONCORDBIOIN:DCALIN:PANACEABIOIN:ANTHEMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SYNGENE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SYNGENESyngene International Ltd.434.05-198.66-31.40%
IN:BIOCONBiocon Limited359.65-35.13-8.90%
IN:CONCORDBIOConcord Biotech Ltd.555.20-160.04-22.38%
IN:DCALDishman Carbogen Amcis Ltd.130.10-115.55-47.04%
IN:PANACEABIOPanacea Biotec Limited353.90-3.35-0.94%
IN:ANTHEMAnthem Biosciences Limited923.95277.8343.00%

Syngene International Ltd. Corporate Events

Syngene posts Q2 FY27 earnings call audio for investors

Oct 28, 2026

Syngene International Limited has notified the Indian stock exchanges that the audio recording of its Q2 FY27 post-earnings call held on October 28, 2026 has been uploaded to the company’s website. The disclosure has been made under Regulation 30 of...

Syngene Publishes Investor Presentation for September 2026 Period

Oct 27, 2026

Syngene International Ltd. has released an investor presentation for the quarter and half year ended September 30, 2026, in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements Regulations, 2015. The document, intended fo...

Syngene Announces Resignation of Corporate Affairs Head

Sep 21, 2026

Syngene International Ltd. has announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and a member of the Executive Committee, effective at the close of business on September 21, 2026. The company has notified the B...

Syngene Schedules Analyst Meet at Kotak Healthcare Forum 2026

Sep 12, 2026

Syngene International Ltd. has scheduled a meeting with analysts and institutional investors at the Healthcare Forum 2026 organized by Kotak in Mumbai on September 17, 2026. The engagement will take place as a physical group and one-on-one investor c...

Syngene Grants 1.43 Million Performance Share Units Under 2023 Long-Term Incentive Plan

Sep 1, 2026

Syngene International has granted 1,426,061 Performance Share Units (PSUs) to eligible employees under its Long Term Incentive Performance Share Plan 2023, following approval by the company’s Nomination and Remuneration Committee. The grant, aligned...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026